SCHEMBL5232194

SCHEMBL5232194

S=C(Nc1ccccc1OCc1ccccc1)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.62
HPGD P15428 1/20 0.62
HTT P42858 1/20 0.62
BRD4 O60885 2/20 0.61
TDP1 Q9NUW8 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MAPK1 P28482 2/20 0.50
PPIA P62937 2/20 0.49
HTR1A P08908 1/20 0.46
DRD2 P14416 1/20 0.46
CYP1A2 P05177 2/20 0.46
GAA P10253 2/20 0.46
ALOX12 P18054 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
SGMS2 Q8NHU3 1/20 0.46
LIPE Q05469 1/20 0.45
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18586598 0.83 BRD4 (0.63) ALDH1A1BRD4TDP1L3MBTL1MAPK1
SCHEMBL38660185 0.81 BRD4 (0.70) ALDH1A1HPGDBRD4TDP1L3MBTL1
SCHEMBL11549645 0.81 BRD4 (0.70) ALDH1A1HPGDBRD4TDP1L3MBTL1
SCHEMBL4985731 0.79 BRD4 (0.67) ALDH1A1HPGDBRD4TDP1L3MBTL1
SCHEMBL3619403 0.79 BRD4 (0.77) BRD4TDP1L3MBTL1MAPK1PPIA
SCHEMBL4297414 0.78 BRD4 (0.74) ALDH1A1HTTBRD4TDP1L3MBTL1
SCHEMBL5148514 0.77 BRD4 (0.63) ALDH1A1HTTBRD4TDP1L3MBTL1
SCHEMBL4322685 0.76 MAPK1 (0.58) ALDH1A1HPGDHTTBRD4TDP1
SCHEMBL28316872 0.76 BRD4 (0.63) ALDH1A1HPGDBRD4TDP1L3MBTL1
SCHEMBL8924076 0.76 BRD4 (1.00) BRD4TDP1L3MBTL1PPIASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1339701-B1 HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS INC (US) 2007-02-14 EP disclosed
US-6849632-B2 Heteroaryl alkyl piperazine derivatives CV THERAPEUTICS, INC. (US) 2005-02-01 US disclosed
US-20040192702-A1 Heteroaryl alkyl piperazine derivatives ZABLOCKI JEFF (US) 2004-09-30 US disclosed
US-20040029889-A1 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. 2004-02-12 US disclosed
US-20030216409-A1 Heteroaryl alkyl piperazine derivatives CV THERAPEUTICS, INC. 2003-11-20 US disclosed
US-6573264-B1 Protecting skeletal muscles against damage, treating shock conditions, preserving donor tissue and organs used in transplants, treating cardiovascular diseases CV THERAPEUTICS, INC. 2003-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029889-A1 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors CPT1B, CPT1A, ALOX15 ALDH1A1 69/4885HPGD 524/4885HTT 4560/4885
US-20040192702-A1 Heteroaryl alkyl piperazine derivatives ATP2A1, CPT1B, ATP2A3 ALDH1A1 110/4885HPGD 1079/4885HTT 4523/4885
US-20030216409-A1 Heteroaryl alkyl piperazine derivatives ATP2A1, CPT1B, ATP2A3 ALDH1A1 110/4885HPGD 1079/4885HTT 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.